ArticleProceedings of the National Academy of Sciences of the United States of America2024
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.Oncogene · 2026Article
- Review
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Castration-resistant prostate cancer as an adaptive tumor ecosystem: coupling tumor evolution with microenvironmental reprogramming.Cancer metastasis reviews · 2026Review
- Long-read sequencing reveals widespread novel splicing and neojunction-derived neoantigens in nasopharyngeal carcinoma.Genome research · 2026Article
- Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival.Cancer research communications · 2026Article
- DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.Drugs · 2026Review
- The Great Escape: the systems biology of endocrine resistance and lineage plasticity.Endocrine-related cancer · 2026Review
- SRRT promotes prostate cancer progression and serves as a prognostic biomarker through STAT3 pathway activation.Oncology reports · 2026Article
- Single-cell-marker-based subtyping and multi-level analyses uncover the prognostic effects, dysregulations and therapeutic indicative potential of an eight-gene signature in lung adenocarcinoma.Cancer cell international · 2026Article
- Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs).Gene · 2026Review
- HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy.Cell death discovery · 2026Article
- Integrative transcriptomic and single-cell analysis reveals metabolic reprogramming and hexosamine biosynthesis-mediated tumor microenvironment remodeling in prostate cancer.Discover oncology · 2026Article
- Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.bioRxiv : the preprint server for biology · 2026Article
- Prognostic biomarkers and Hedgehog pathway activation in early prostate cancer neuroendocrine differentiation via spatial profiling.NPJ precision oncology · 2026Article
- Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.The Journal of clinical investigation · 2026Article
- Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation.Cell death discovery · 2026Article
- Integrated single-cell and spatial transcriptomic profiling decodes lineage plasticity and immune microenvironment remodeling in prostate cancer progression.Molecular cancer · 2026Article
- EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression.Cancer research · 2026Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
34 authors.
Samir ZaidiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Jooyoung ParkDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Korea.ORCID 0000-0001-9001-6388
Joseph M ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Martine P RoudierDepartment of Urology, University of Washington, Seattle, WA 98195.
Jimmy L ZhaoAstrazeneca Oncology R&D, New York, NY 10016.
Anuradha GopalanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Kristine M WadoskyDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263.
Radhika A PatelDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98195.
Erolcan SayarDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98195.ORCID 0000-0002-3922-5683
Wouter R KarthausSwiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.
D Henry KatesHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Ojasvi ChaudharyProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Tianhao XuProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Ignas MasilionisProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Linas MazutisProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Ronan ChalignéProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Aleksandar ObradovicDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032.
Irina LinkovDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Afsar BarlasMolecular Cytology Core Facility, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York NY 10065.
Achim A JungbluthDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Natasha RekhtmanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Joachim SilberDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Katia Manova-TodorovaMolecular Cytology Core Facility, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York NY 10065.
Philip A WatsonResearch Outreach and Compliance, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Lawrence D TrueDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, WA 98195.
Howard I ScherDepartment of Medicine, Division of Solid Tumor Oncology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Dana E RathkopfDepartment of Medicine, Division of Solid Tumor Oncology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Michael J MorrisDepartment of Medicine, Division of Solid Tumor Oncology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-9454-0096
David W GoodrichDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263.
Jungmin ChoiDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Korea.ORCID 0000-0002-8614-0973
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98195.
Michael C Haffner *Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98195.
Charles L Sawyers *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0003-4955-6475
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1MProject 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4MYAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistanceU24CA274159 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DAVID W. GOODRICH, Alan David Hutson · 2022 to 2026
$8.5MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MNOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancerR01CA234162 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOODRICH, DAVID W. · 2019 to 2024
$3.0MRequirements for Normal Rb Function In VivoR01CA070292 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI GOODRICH, DAVID W. · 1996 to 2010
$2.9MAugmenting PSMA expression to enhance PSMA directed therapeutic efficacyR37CA286450 · NCI · FRED HUTCHINSON CANCER CENTER · PI Michael C Haffner, Michael T Schweizer · 2024 to 2026
$2.1MDefining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate CancerR01CA234715 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NELSON, PETER S · 2020 to 2024
$2.0MHHS | NIH | National Cancer Institute (NCI) CA155169Howard Hughes Medical Institute (HHMI) NANCI NIH HHS K08 CA259161NCI NIH HHS K08 CA282978NCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA070292NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA234162NCI NIH HHS R01 CA234715NCI NIH HHS R01 CA266452NCI NIH HHS R21 CA277368NCI NIH HHS R37 CA286450NCI NIH HHS U24 CA274159NCI NIH HHS U54 CA224079
Abstract
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)-a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival. To understand how lineage markers vary across the evolution of lineage plasticity in prostate cancer, we applied single-cell analyses to 21 human prostate tumor biopsies and two genetically engineered mouse models, together with tissue microarray analysis on 131 tumor samples. Not only did we observe a higher degree of phenotypic heterogeneity in castrate-resistant PRAD and NEPC than previously anticipated but also found that the expression of molecules targeted therapeutically, namely
Indexed as
Single-Cell AnalysisAdenocarcinomaAnimalsAntigens, NeoplasmAntigens, SurfaceBiomarkers, TumorCarcinoma, NeuroendocrineGene Expression Regulation, NeoplasticHumansMaleMiceProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAntigens, NeoplasmAntigens, SurfaceBiomarkers, Tumorcell statesepithelial maliganciesheterogeneitylineage plasticity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.